CELLPOINT
28.3.2022 01:02:12 CEST | Business Wire | Press release
CellPoint Digital , a leading global provider of Digital Commerce and Payment Orchestration solutions, today announces a new partnership with Virgin Atlantic and Virgin Holidays .
The airline and holiday package provider will use CellPoint Digital’s full payment orchestration platform to seamlessly integrate new payment methods, new acquirers and stored card facilities, enabling reduced costs, increased acceptance rates and a better customer experience.
By orchestrating payments across regions and payment methods, CellPoint Digital’s innovative platform allows merchants to adopt a multi-acquirer payments model that opens new opportunities for growth. It also helps increase top-line revenue utilising intelligent routing, increasing authorisations, and providing system uptime transparency, and reduces the operation cost of accepting cross border payments.
News of the Virgin deal comes after a series of investments by Toscafund and Penta Capital into CellPoint Digital, which brings their total investment to more than $56M.
Yasin Demir, head of distribution and payments at Virgin Atlantic, added: “We identified CellPoint Digital as specialists in payment orchestration, providing a unique and innovated mind set towards the airline payments ecosystem. Its offering aligns perfectly with our plans to add multiple new acquirers and payment methods and we are looking forward to working with them in the coming months and beyond.”
Kristian Gjerding, CEO at CellPoint Digital, commented: “Virgin is one of the largest carriers in the UK and we are excited to be working with a brand that has such an incredible global reputation. As the project progresses, we will be collaborating closely with the Virgin payments team to ensure they get maximum benefit from our payment orchestration platform.
“By utilising our comprehensive payment orchestration platform and having access to a large payments ecosystem, we can enhance the payment process for Virgin Atlantic and Holidays while bolstering its offering with popular alternative payment methods for its customers.
Our Payment Orchestration Platform will give Virgin access to a much larger payment ecosystem and enable it to offer customers their preferred method of payment for the countries it flies to. As we emerge from the pandemic, fewer travellers are using cards to purchase tickets, with the convenience of mobile devices, e-wallet options and QR codes transforming the way they pay for airline tickets. Recent research has highlighted that 84% of travellers now pay with alternative payment methods.”
CellPoint Digital’s powerful omni-channel Payment Orchestration Platform optimises digital payment transactions, from cards or alternative payment methods, and accelerates the deployment of new payment options. Users can easily scale their own payment ecosystem across the world, unify the customer payment experience across their website, mobile apps and other channels, optimise the routing of each transaction, increase conversion rate and minimise payment costs.
To find out more, visit https://cellpointdigital.com/
ENDS
About CellPoint Digital
CellPoint Digital is a fintech leader in payment orchestration. CellPoint Digital’s main solution is a powerful omni-channel Payment Orchestration Platform that optimises digital payment transactions, from cards or alternative payment methods, and accelerates the deployment of new payment options. Merchants can easily scale their own payment ecosystem across the world, unify the customer payment experience across their website, mobile apps and other channels, optimize the routing of each transaction, increase conversion rates and minimise payment costs. Toscafund and Penta Capital have invested more than $56 million into CellPoint Digital.
CellPoint Digital has offices in Copenhagen, Dallas, Dubai, London, Miami, Pune and Singapore.
About Virgin Atlantic
Virgin Atlantic first took to the skies in 1984, instantly shaking things up and attracting plenty of attention. Since then Virgin Atlantic has become the UK’s second largest carrier, helping customers to fly and connect all around the world, with non-stop transatlantic routes including New York, Los Angeles, Hong Kong, Delhi and Johannesburg. Plus, thanks to the joint venture with Delta, Air France and KLM, over 350 cities across North America, Europe and the UK have now become accessible.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220327005040/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom